文献速递浆细胞疾病

帕博利珠单抗、泊马度胺联合低剂量地塞米松治疗复发/难治性多发性骨髓瘤

Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.
PubMed 文献 · Blood · 2017-05-01

这项单中心2期研究纳入48例复发/难治性多发性骨髓瘤患者,接受帕博利珠单抗、泊马度胺和低剂量地塞米松治疗。客观缓解率为60%(29/48),中位缓解持续时间14.7个月,中位随访15.6个月时中位无进展生存期17.4个月,总生存期未达到。3-4级不良事件发生率为40%(19/48)。

要点

  • 客观缓解率60%(29/48),其中严格完全缓解/完全缓解8%(4/48)。
  • 中位无进展生存期17.4个月,中位随访15.6个月时总生存期未达到。
  • 3-4级不良事件40%(19/48),自身免疫事件多为2级及以下。

核心结论

  • 帕博利珠单抗、泊马度胺联合低剂量地塞米松在复发/难治性多发性骨髓瘤患者中具有可接受的安全性和持久的缓解。

研究设计与样本

  • 单中心、2期研究,纳入48例复发/难治性多发性骨髓瘤患者。
  • 治疗方案为28天周期:帕博利珠单抗200 mg静脉注射每2周一次,泊马度胺4 mg每日一次连用21天,地塞米松40 mg每周一次。
  • 患者既往中位治疗线数为3线(范围2-5线),中位年龄64岁(范围35-83岁)。

主要发现

  • 48例中35例(73%)对免疫调节药物和蛋白酶体抑制剂均难治;31例(70%)曾接受自体移植;30例(62%)具有高危细胞遗传学。
  • 3-4级不良事件发生于19/48例(40%),包括血液学毒性19/48例(40%)、高血糖12/48例(25%)、肺炎7/48例(15%)。
  • 自身免疫事件包括肺炎6/48例(13%)和甲状腺功能减退5/48例(10%),大多≤2级。
  • 客观缓解29/48例(60%),其中严格完全缓解/完全缓解4/48例(8%)、非常好的部分缓解9/48例(19%)、部分缓解16/48例(33%);中位缓解持续时间14.7个月。
  • 中位随访15.6个月时,无进展生存期为17.4个月,总生存期未达到。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Programmed death 1 (PD-1) receptor and its ligand (PD-L1) facilitate immune evasion in multiple myeloma (MM). We hypothesized that pembrolizumab, PD-1-antibody, can enhance antimyeloma cellular immunity generated by pomalidomide, leading to improved clinical responses. In this single-center, phase 2 study, 48 patients with relapsed/refractory MM (RRMM) received 28-day cycles of pembrolizumab, 200 mg IV every 2 weeks, pomalidomide 4 mg daily for 21 days, and dexamethasone 40 mg weekly. Patients had a median of 3 (range: 2-5) lines of therapy, median age 64 (range: 35-83) years, and had received both an immune modulatory drug (IMiD) and proteasome inhibitor: (35 [73%] of 48) were refractory to both; (31 [70%]) had received an autologous transplant, and (30 [62%]) had high-risk cytogenetics. Adverse events grade 3 to 4 occurred in (19 [40%] of 48 patients), including hematologic toxicities (19 [40%]), hyperglycemia (12 [25%]), and pneumonia (7 [15%]). Autoimmune events included pneumonitis (6 [13%]) and hypothyroidism (5 [10%]), mostly ≤ grade 2. Objective responses occurred in (29 [60%] of 48) patients, including stringent complete response/complete response (4 [8%]), very good partial response (9 [19%]), and partial response (16 [33%]); median duration of response was 14.7 months. At median follow-up of 15.6 months, progression-free survival (PFS) was 17.4 months and overall survival was not reached. Analyses of pretreatment marrow samples revealed a trend for increased expression of PD-L1 in responding patients and longer PFS with increased T-lymphocyte infiltrates, irrespective of PD-1 expression. Pembrolizumab, pomalidomide, and low-dose dexamethasone have acceptable safety and durable responses in RRMM patients. This trial was registered at www.clincialtrials.gov as #NCT02289222.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017. PMID: 28461396. doi:10.1182/blood-2017-03-775122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。